Portal de Periódicos da CAPES

Ginkgo biloba extract for age-related macular degeneration

1999; Cochrane; Linguagem: Inglês

10.1002/14651858.cd001775

1469-493X

Jennifer Evans,

Cerebrovascular and genetic disorders

Background Ginkgo is used in the treatment of peripheral vascular disease and 'cerebral insufficiency'. It is thought to have several potential mechanisms of action including increased blood flow, platelet activating factor antagonism, and prevention of membrane damage caused by free radicals. Vascular factors and oxidative damage are thought to be two potential mechanisms in the pathology of age‐related macular degeneration (AMD). Objectives The objective of this review was to determine the effect of Ginkgo biloba extract on the progression of AMD. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2008, Issue 4), MEDLINE (January 1966 to December 2008), EMBASE (January 1980 to December 2008), OpenSIGLE (1980 to December 2008), AMED (January 1985 to December 2008), UK Clinical Trials Gateway (December 2008), reference lists of identified trial reports, and the Science Citation Index. We also contacted investigators of included studies for additional information. Selection criteria All randomised trials in people with AMD where Ginkgo biloba extract had been compared to control were included. Data collection and analysis The review author extracted data using a standardised form. The data were verified with the trial investigators. Trial quality was assessed. Main results Two published trials were identified. However, these trials were small (20 and 99 participants) and their results could not be pooled because they had different comparisons. Adverse effects and quality of life for people with AMD were not reported. Authors' conclusions The question as to whether people with AMD should take Ginkgo biloba extract to prevent progression of the disease has not been answered by research to date.